Equities

Bio Essence Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BIOE:PKC

Bio Essence Corp

Actions
  • Price (USD)0.0546
  • Today's Change0.00 / 0.00%
  • Shares traded11.20k
  • 1 Year change-83.94%
  • Beta--
Data delayed at least 15 minutes, as of Feb 03 2026 17:40 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bio Essence Corp. is a herbal health, diet, and nutrition company. The Company is mainly engaged in selling health supplements and providing original equipment manufacturing (OEM) services. The Company also outsources manufacturing / OEM services.

  • Revenue in USD (TTM)565.67k
  • Net income in USD-160.45k
  • Incorporated2000
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Evofem Biosciences Inc17.73m-5.56m1.10m32.00------0.0622-0.058-0.0580.0111-0.56610.93922.253.61553,937.50-28.79-177.41----80.0569.60-30.66-602.270.0797-0.2439----6.28---117.93---38.87--
Onconetix Inc1.22m-50.85m1.20m5.00--0.3581--0.9839-350.74-350.742.142.160.031.3124.33244,750.00-120.44-82.49-240.72-114.7185.41---4,015.56-4,434.980.0706-17.940.0453--4,216.95---57.44--44.62--
Procyon Corp4.98m-312.97k1.53m19.00--0.7027--0.307-0.0387-0.03870.61380.28171.472.329.90262,338.40-10.081.19-12.701.4478.0774.40-6.840.86912.41--0.00--6.353.53-367.38--17.32--
Universe Pharmaceuticals Inc17.86m-3.67m1.61m216.00--0.0287--0.0902-10.13-10.1339.1899.640.26025.881.3882,679.35-5.35-5.40-7.08-7.0935.2843.33-20.56-9.653.90-17.460.1416---22.44-10.2757.92--46.30--
Stemcell Holdings Inc9.98m3.10m1.64m------0.50080.16450.000080.000080.00030.00021.12--5.20--34.90--68.19--77.19--31.04------0.00--85.10--71.82------
Panacea Life Sciences Holdings Inc2.76m-7.67m1.90m40.00------0.6858-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.122.58--46.59--12.33------
Bio Essence Corp565.67k-160.45k2.08m2.00------3.67-0.0042-0.00420.0149-0.08161.26--16.06282,835.00-35.64-40.94----69.2838.36-28.36-134.00---57.42-------17.08-286.98------
InVitro International716.89k6.22k2.21m16.00284.003.09--3.090.00040.00040.04020.03211.15------0.9957.891.098.83----0.86765.90---------5.111.33-87.77-16.14----
PRF Technologies Ltd0.00-4.09m2.32m2.000.00980.1412----301.27301.270.0020.970.00----0.00-57.27-71.03-118.06-84.02------------0.00-------56.12------
Scisparc Ltd-100.00bn-100.00bn2.59m2.00---------------1.46-----------63.15---90.87-------456.810.5151--1.04---54.64---22.69------
SOHM Inc-100.00bn-100.00bn2.60m--------------------------------------------------------------
Jaguar Health Inc11.79m-40.29m2.87m49.00--0.7415--0.2433-54.06-54.0612.981.530.21840.20998.78240,510.20-76.04-90.27-152.77-144.3681.9275.33-348.22-458.250.5197-4.620.8759--19.7515.146.80------
Data as of Feb 03 2026. Currency figures normalised to Bio Essence Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.